Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 8:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,847 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dexamethasone/Dexamethasone acetate Clear all
Terminated Phase 1Phase 2 Interventional Results available

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

NCT01997840
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 10, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 4 (ACTT-4)

NCT04640168
View directory record Official record
Conditions
COVID-19
Interventions
Baricitinib, Dexamethasone, Placebo, Remdesivir
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
61
States / cities
Birmingham, Alabama • Fresno, California • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 10, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00103285
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
3-Dimensional Conformal Radiation Therapy, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine Sulfate
Radiation · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 9 Years
Enrollment
5,377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2021
U.S. locations
210
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 10, 2026, 8:45 PM EDT
Completed Phase 2 Interventional

Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency

NCT01337752
View directory record Official record
Conditions
Multiple Myeloma, Renal Insufficiency
Interventions
BHQ880, BHQ880 Placebo, bortezomib, dexamethasone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Chicago, Illinois • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 10, 2026, 8:45 PM EDT
Completed Phase 2 Interventional

Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma

NCT00003007
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
recombinant interferon alfa, sargramostim, cyclophosphamide, dexamethasone, melphalan, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Tennessee
Other
Eligibility
19 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
4
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 10, 2026, 8:45 PM EDT
Completed Phase 1 Interventional

Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

NCT01204164
View directory record Official record
Conditions
AML, ALL, Blast Crisis, MDS, Multiple Myeloma
Interventions
TG02 citrate, Carfilzomib, Dexamethasone
Drug
Lead sponsor
Tragara Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
9
States / cities
Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 10, 2026, 8:45 PM EDT
Withdrawn Phase 4 Interventional

Intraoperative Dexamethasone and Its Effect on Hyperglycemia

NCT03646916
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Dexamethasone, No dexamethasone
Drug · Other
Lead sponsor
Ascension Health
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Grand Blanc, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 10, 2026, 8:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Measurement of Pituitary Volume and Hormonal Changes in Patients With Post-traumatic Stress Disorder

NCT00815204
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
MRI of the pituitary, DEX/CRH test
Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2015 · Synced Oct 10, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

Corticosteroids for Children With Febrile Urinary Tract Infections

NCT01391793
View directory record Official record
Conditions
Acute Urinary Tract Infection, Urinary Tract Infection
Interventions
Placebo, Dexamethasone
Drug
Lead sponsor
Nader Shaikh
Other
Eligibility
2 Months to 6 Years
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Columbus, Ohio • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 10, 2026, 8:45 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

NCT04091126
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin, Bortezomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
3
States / cities
Westwood, Kansas • Charlotte, North Carolina • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 10, 2026, 8:45 PM EDT
Completed Phase 2 Interventional Results available

Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger

NCT00290498
View directory record Official record
Conditions
Lymphoma
Interventions
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone, Methotrexate, Cytarabine, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years to 60 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 10, 2026, 8:45 PM EDT
Completed Not applicable Interventional Results available

Peri-Operative Steroid Management in Patients

NCT02084134
View directory record Official record
Conditions
Pituitary Adenoma, Pituitary Diseases
Interventions
hydrocortisone, dexamethasone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Oct 10, 2026, 8:45 PM EDT
Terminated Phase 4 Interventional Results available

Continuous Nerve Block Block vs Combination of Single Block Plus Intravenous Lidocaine for Postoperative Pain.

NCT04208516
View directory record Official record
Conditions
Postoperative Pain
Interventions
Continuous Erector Spinae Plane Nerve Block, Continuous Quadratus Lumborum Nerve Block, Single Erector Spinae Plane Nerve Block, Single Quadratus Lumborum Nerve Block, Lidocaine IV, Ropivacaine 0.5% Injectable Solution, Dexamethasone, Dexmedetomidine, Lidocaine
Procedure · Drug
Lead sponsor
Jeremy Kearns
Other
Eligibility
18 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 10, 2026, 8:45 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

NCT04752163
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
Interventions
DS-1594b, Azacitidine, Cyclophosphamide, Cytarabine, Dexamethasone, Filgrastim, Leucovorin, Mesna, Methotrexate, Prednisone, Rituximab, Venetoclax, Vincristine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 10, 2026, 8:45 PM EDT
Recruiting Phase 4 Interventional

BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron

NCT04150614
View directory record Official record
Conditions
Nausea With Vomiting Chemotherapy-Induced
Interventions
Granisetron Transdermal Patch, Intravenous Dexamethasone, Ondansetron
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 10, 2026, 8:45 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma

NCT01090921
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib
Drug
Lead sponsor
Boston VA Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
11
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 10, 2026, 8:45 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma

NCT02951819
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
26
States / cities
Mobile, Alabama • Phoenix, Arizona • Sedona, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 10, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study

NCT01311687
View directory record Official record
Conditions
Multiple Myeloma
Interventions
pomalidomide, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 10, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

NCT06729593
View directory record Official record
Conditions
Covid19
Interventions
Remdesivir, Remdesivir Placebo, Corticosteroid
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 10, 2026, 8:45 PM EDT
Terminated Phase 1 Interventional

An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)

NCT01742793
View directory record Official record
Conditions
Hodgkin's Lymphoma, Mature T-cell Lymphoma, Multiple Myeloma
Interventions
lenalidomide (Revlimid) and romidepsin (Istodax)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 10, 2026, 8:45 PM EDT
Withdrawn Phase 4 Interventional

The Effect of a Methylprednisolone Taper on Outcomes Following Total Knee Arthroplasty

NCT06489626
View directory record Official record
Conditions
Arthritis Knee, Knee Osteoarthritis, Pain, Postoperative
Interventions
Methylprednisolone 4 milligram Tab, Dexamethasone injection
Drug
Lead sponsor
F. Johannes Plate
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Monroeville, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 10, 2026, 8:45 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Detection of miRNAs in HPA Axis Function in Healthy Subjects

NCT04066647
View directory record Official record
Conditions
Dexamethasone Effect on miRNA Profile in Healthy Humans
Interventions
Dexamethasone 4mg
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Oct 10, 2026, 8:45 PM EDT
Completed Phase 1 Interventional

A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT01400555
View directory record Official record
Conditions
Prostate Neoplasms, Prostate Cancer
Interventions
Cohort 4, Cohort 3, Cohort 2, Cohort 1
Drug
Lead sponsor
Cougar Biotechnology, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 10, 2026, 8:45 PM EDT
Completed Not applicable Interventional

Factors Affecting the Speed of Recovery After ACL Reconstruction

NCT03770806
View directory record Official record
Conditions
Anterior Cruciate Ligament Injury, ACL Injury, ACL - Anterior Cruciate Ligament Rupture
Interventions
Femoral Nerve Block, Adductor Nerve Block, No Block
Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Oct 10, 2026, 8:45 PM EDT